Celldex Therapeutics
CLDX
Celldex Therapeutics (CLDX) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Barclays | Maintained | Overweight | $53.00 from $48.00 | Aug 7, 2026 |
| Morgan Stanley | Maintained | Overweight | $46.00 from $40.00 | Aug 7, 2026 |
| Wells Fargo | Maintained | Overweight | $72.00 from $48.00 | Jul 29, 2026 |
| Canaccord Genuity | Maintained | Buy | $60.00 from $62.00 | Jul 22, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $61.00 from $67.00 | Jul 22, 2026 |
| Morgan Stanley | Maintained | Overweight | $40.00 from $44.00 | Jul 22, 2026 |
| Wells Fargo | Maintained | Overweight | $48.00 from $54.00 | Jul 22, 2026 |
| Guggenheim | Maintained | Buy | $100.00 from $90.00 | Jul 20, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $42.00 | Jun 15, 2026 |
| UBS | Maintained | Buy | $45.00 from $38.00 | Jun 10, 2026 |
| Wells Fargo | Maintained | Overweight | $54.00 from $38.00 | May 13, 2026 |
| Barclays | Maintained | Overweight | $48.00 from $45.00 | May 8, 2026 |
| Barclays | Upgraded | Underweight → Overweight | $45.00 from $24.00 | Apr 20, 2026 |
| Goldman Sachs | Maintained | Neutral | $34.00 from $30.00 | Mar 2, 2026 |
| Stifel | Maintained | Buy | $68.00 from $58.00 | Feb 26, 2026 |
| Barclays | Maintained | Underweight | $24.00 from $21.00 | Dec 17, 2025 |
| Barclays | Maintained | Underweight | $21.00 from $25.00 | Nov 11, 2025 |
| Mizuho | Initiated Coverage | Outperform | $48.00 | Oct 21, 2025 |
| Barclays | Initiated Coverage | Underweight | $25.00 | Oct 13, 2025 |
| Canaccord Genuity | Maintained | Buy | $62.00 | Sep 17, 2025 |
Frequently asked questions
What is the latest analyst rating on CLDX?
On Aug 7, 2026, Barclays maintained Celldex Therapeutics at Overweight with a price target of $53.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.